Healthcare Services

Rising Prevalence Of Long-Term Hepatitis Infections Driving Growth In The Market Continues To Impact The Growth Of The Advanced Liver Cancer Market

May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Advanced Liver Cancer Market By 2030 Based On Its 2026 Value?

The market for advanced liver cancer treatments has experienced swift expansion in recent years. This market is projected to expand from $2.16 billion in 2025 to $2.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion can be linked to factors such as an increasing occurrence of liver cancer, the greater use of CT and MRI imaging, a rising need for biopsy procedures, boosted funding for cancer research, and the establishment of more diagnostic centers and academic institutions.

The advanced liver cancer market is projected to undergo substantial growth over the coming years. It is forecast to achieve a valuation of $4.27 billion by 2030, with a compound annual growth rate (CAGR) of 14.5%. This projected increase within the forecast period is primarily driven by advancements in genomic testing technologies, the increasing integration of personalized medicine, the expansion of screening and predictive diagnostics, a rise in collaborations between hospitals and research centers, and the broadening of ambulatory surgical centers. Significant trends expected during this period involve the increasing adoption of ngs and genomic testing for hcc, enhanced utilization of imaging and biopsy techniques, growth in prognostic and predictive diagnostics, the expansion of liver cancer research initiatives, and a dedicated focus on early detection and personalized treatment approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp

Which Strategic Drivers Are Supporting The Advanced Liver Cancer Market Development?

The increasing incidence of prolonged hepatitis infections is projected to fuel the expansion of the advanced liver cancer market. These protracted viral infections, defined as lasting over six months, can lead to liver damage, cirrhosis, or liver cancer. The rise in such infections is linked to factors such as inadequate screening, insufficient vaccination, and delayed access to treatment. Chronic infections with hepatitis B (HBV) or hepatitis C (HCV) are primary causes of liver cirrhosis and hepatocellular carcinoma (HCC), which is the most common form of liver cancer, as these long-term viral infections can progressively cause liver inflammation, damage, and ultimately cancer. With the ongoing prevalence of these infections, more individuals face the risk of developing advanced liver cancer. For instance, in April 2025, ASHM, an Australia-based peak organisation of health professionals, stated that in 2023, approximately 219,800 individuals in Australia were living with chronic hepatitis B (CHB), accounting for around 0.82% of the country’s population. Therefore, the growing prevalence of long-term hepatitis infections is significantly driving the growth of the advanced liver cancer market.

What Are The Major Segment Categories Within The Advanced Liver Cancer Market?

The advanced liver cancer market covered in this report is segmented –

1) By Test Type: Imaging Test, Biopsy, Genomic Test, Other Test Types

2) By Technology: Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, Other Technologies

3) By Distribution Channel: Direct Tenders, Retail Sales, Other Distribution Channel

4) By Application: Diagnostic And Predictive, Prognostic, Research

5) By End-User: Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Other End-Users

Subsegments:

1) By Imaging Test: Ultrasound, CT (Computed Tomography) Scan, MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) Scan

2) By Biopsy: Needle Biopsy, Laparoscopic Biopsy, Surgical Biopsy

3) By Genomic Test: Next-Generation Sequencing (NGS), PCR (Polymerase Chain Reaction) Testing, Genetic Mutation Profiling

4) By Other Test Types: Serum Biomarker Testing, Liver Function Tests, Alpha-Fetoprotein (AFP) Test, Elastography Tests

What Trends Are Affecting The Advanced Liver Cancer Market Dynamics?

Leading organizations within the advanced liver cancer market are directing their efforts towards establishing integrated multidisciplinary clinics. These clinics are designed to elevate patient-centric care, enhance the coordination of treatments, and streamline clinical decision-making processes. Such a multidisciplinary clinic assembles specialists from fields like oncology, hepatobiliary surgery, interventional radiology, genetics, pathology, anesthesia, and palliative care. Their collaborative approach allows for the comprehensive planning of therapies for intricate liver cancer cases, guaranteeing personalized interventions and reducing procedural delays. An illustrative instance occurred in July 2025, when Apollo Proton Cancer Centre, a cancer-treatment provider based in India, inaugurated its Advanced Liver Cancers Clinic. This facility integrates care for both primary liver cancers and liver metastases under one roof. It convenes medical oncologists, hepatobiliary surgeons, interventional radiologists, geneticists, pathologists, and palliative care experts to institute standardized treatment pathways. Furthermore, the clinic intends to undertake prospective research, explore novel therapeutic approaches, and prioritize the patient’s entire care journey, thereby addressing the growing necessity for specialized liver cancer programs in India amidst a surging prevalence of hepatocellular carcinoma, which is exacerbated by hepatitis, fatty liver disease, and delayed diagnoses.

Which Companies Are Engaged In The Advanced Liver Cancer Market Environment?

Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.

Access The Complete Advanced Liver Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer-global-market-report

Which Region Is The Dominant Market In The Advanced Liver Cancer Market?

North America was the largest region in the advanced liver cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Advanced Liver Cancer Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20706&type=smp

Browse Through More Reports Similar to the Global Advanced Liver Cancer Market 2026, By The Business Research Company

Liver Diseases Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Buccal Drug Delivery System Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

Human Liver Model Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/human-liver-model-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795